Haleon PLC Advances Share Buyback Program with New Purchase

Haleon PLC ( (GB:HLN) ) has shared an announcement.

Haleon PLC announced the purchase of 1,500,000 ordinary shares as part of the second tranche of its share buyback program. The shares will be held as treasury shares, impacting the company’s share capital and voting rights. This move reflects Haleon’s strategic financial management and may influence shareholder decisions under the FCA’s Disclosure Guidance and Transparency Rules.

The most recent analyst rating on (GB:HLN) stock is a Buy with a £398.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.

Spark’s Take on GB:HLN Stock

According to Spark, TipRanks’ AI Analyst, GB:HLN is a Outperform.

Haleon PLC’s overall stock score reflects a strong financial foundation with robust profitability and cash flow management. However, technical indicators and valuation suggest a more cautious outlook. The earnings call highlighted regional strengths but also significant challenges in North America, impacting the overall sentiment. The absence of notable corporate events leaves the focus on financial and operational performance.

To see Spark’s full report on GB:HLN stock, click here.

More about Haleon PLC

Haleon PLC is a global leader in consumer health, focusing on delivering better everyday health through a diverse product portfolio. The company operates in six major categories: Oral Health, Vitamins, Minerals and Supplements, Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health. Haleon is known for its trusted brands like Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu, and Voltaren, which are built on a foundation of science, innovation, and human understanding.

Average Trading Volume: 20,194,847

Technical Sentiment Signal: Buy

Current Market Cap: £32.39B

For detailed information about HLN stock, go to TipRanks’ Stock Analysis page.